Tripep discontinues HIV drug

Tripep (SSE:TPEP) said its Phase II study of GPG tripeptide lysine proline glycine for HIV has not shown

Read the full 186 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE